CoChat

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Open access
Fabiani, Massimo, Puopolo, Maria, Morciano, Cristina, Spuri, Matteo, Spila Alegiani, Stefania, Filia, Antonietta, D’Ancona, Fortunato, Del Manso, Martina, Riccardo, Flavia, Tallon, Marco, Proietti, Valeria, Sacco, Chiara, Massari, Marco, Da Cas, Roberto, Mateo-Urdiales, Alberto, Siddu, Andrea, Battilomo, Serena, Bella, Antonino, Palamara, Anna Teresa, Popoli, Patrizia, Brusaferro, Silvio, Rezza, Giovanni, Menniti Ippolito, Francesca, Pezzotti, Patrizio · 2022 · BMJ
Cited by 112

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objectives: To estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination. Design: Retrospective cohort study. Setting: Italy, 27 December 2020 to 7 November 2021. Participants: 33 250 344 people aged ≥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection. Main outcome measures: SARS-CoV-2 infection and severe covid-19 (admission to hospital or death). Data were divided by weekly time intervals after vaccination. Incidence rate ratios at different time intervals were estimated by multilevel negative binomial models with robust variance estimator. Sex, age group, brand of vaccine, priority risk category, and regional weekly incidence in the general population were included as covariates. Geographic region was included as a random effect. Adjusted vaccine effectiveness was calculated as (1−IRR)×100, where IRR=incidence rate ratio, with the time interval 0-14 days after the first dose of vaccine as the reference. Results: During the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (P<0.001) from 82% (95% confidence interval 80% to 84%) at 3-4 weeks after the second dose of vaccine to 33% (27% to 39%) at 27-30 weeks after the second dose. In the same time intervals, vaccine effectiveness against severe covid-19 also decreased (P<0.001), although to a lesser extent, from 96% (95% to 97%) to 80% (76% to 83%). High risk people (vaccine effectiveness −6%, −28% to 12%), those aged ≥80 years (11%, −15% to 31%), and those aged 60-79 years (2%, −11% to 14%) did not seem to be protected against infection at 27-30 weeks after the second dose of vaccine. Conclusions: The results support the vaccination campaigns targeting high risk people, those aged ≥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle. The results also suggest that timing the booster dose earlier than six months after the primary vaccination cycle and extending the offer of the booster dose to the wider eligible population might be warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj-2021-069052

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 112

Metadata

Authors
Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Spila Alegiani, S., Filia, A., D’Ancona, F., Del Manso, M., Riccardo, F., Tallon, M., Proietti, V., Sacco, C., Massari, M., Da Cas, R., Mateo-Urdiales, A., Siddu, A., Battilomo, S., Bella, A., Palamara, A. T., Popoli, P., Brusaferro, S., Rezza, G., Menniti Ippolito, F., & Pezzotti, P.
Venue
BMJ
Publisher
BMJ
Published
2022-02-10
Volume
376
Pages
e069052
ISSN
1756-1833 (ISSN-L)
OpenAlex
W4211029192
Cited by
112
References
16
FWCI
12.48
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. https://app.cochat.ai/papers/10.1136/bmj-2021-069052
The paper
Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Spila Alegiani, S., Filia, A., D’Ancona, F., Del Manso, M., Riccardo, F., Tallon, M., Proietti, V., Sacco, C., Massari, M., Da Cas, R., Mateo-Urdiales, A., Siddu, A., Battilomo, S., Bella, A., Palamara, A. T., . . . Pezzotti, P. (2022). Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. https://doi.org/10.1136/bmj-2021-069052

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.